Status | Study |
RECRUITING |
Study Name: Virologic and Immunologic Characteristics of Severe Mpox in Persons With Advanced HIV Condition: Monkeypox Date: 2023-09-01 |
RECRUITING |
Study Name: A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines Condition: Monkeypox Date: 2023-08-04 Interventions: Multivalent ribonucleic acid (RNA)-based vaccine for active immunization against monkeypox administered as intramuscular injection |
ACTIVE_NOT_RECRUITING |
Study Name: A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox Condition: Monkeypox Date: 2023-02-13 Interventions: JYNNEOS is FDA-approved and licensed as a smallpox and monkeypox vaccine in the United States.JYNNEOS is a live vaccine produced from the strain |
Recruiting |
Study Name: IMVAMUNE® Smallpox Vaccine in Adult Healthcare Personnel at Risk for Monkeypox in the Democratic Republic of the Congo Condition: Monkeypox Virus Infection Date: 2016-09-07 Interventions: Biological: IMVAMUNE® Two doses of attenuated live virus smallpox vaccine (IMVAMUNE®) administ |
Available |
Study Name: Tecovirimat (ST-246) Treatment for Orthopox Virus Exposure Condition: Smallpox Monkeypox Date: 2014-03-04 Interventions: Drug: Tecovirimat Oral tablet 600mg daily dose(three capsules, 200 mg/capsule) |
Completed |
Study Name: A Multicenter, Open-label Study of CMX001 Treatment of Serious Diseases or Conditions Caused by dsDNA Viruses Condition: Male or Female Patients With a Serious or Immediately Life-threatening Disease or Condition Date: 2010-06-11 Interventions: Drug: CMX001 CMX001 administered orally twice weekly for up to 3 months. Treatment may be extended for u |
Completed |
Study Name: Phase I Trial of an Investigational Small Pox Medication Condition: Orthopoxviral Disease Smallpox Monke Date: 2008-08-01 Interventions: Drug: ST-246 Days 1 - 3 First |
Withdrawn |
Study Name: SIGA-246 to Treat Smallpox Condition: Vaccinia Date: 2006-03-14 Interventions: Drug: Vaccine: SIGA-246 |